Laboratórna Diagnostika
Published April 13, 2022 | Version v1
Journal article Open

Nový fenotypový klasifikačný systém dyslipidémií založený na štandardnom lipidovom paneli / New phenotypic classification system for dyslipidemias based on the standard lipid panel

Authors/Creators

  • 1. Oddelenie klinickej biochémie a hematológie, Psychiatrická Nemocnica Michalovce, n.o., Michalovce; Klinická epidemiológia a bioštatistika, Košice
  • 2. Klinická epidemiológia a bioštatistika, Košice

Description

Súhrn

Po prehľade doterajších fenotypových klasifikácií dyslipidémií popisujeme nový fenotypový klasifikačný systém dyslipidémií, založený na štandardnom lipidovom paneli -  cholesterol, HDL-cholesterol a triacylglyceroly - ktorého autormi sú Maureen Sampson a spolupracovníci (2021) a upravujeme ho na použitie v SI jednotkách.

Abstract

We describe new phenotypic classification system for dyslipidemias based on the standard lipid panel - cholesterol, HDL-cholesterol and triglycerides - by Maureen Sampson and co-workers (2021) and modify it to use SI units.

Files

Laboratórna Diagnostika XXVII_1_2022 39-45.pdf

Files (1.8 MB)

Name Size
md5:b59311a97dc3511ce36a40d8dbc1a7bb
1.8 MB Preview Download

Additional details

References

  • Adler-Milstein, J., Chen, J.H., Dhaliwal, G. (2021) "Next-Generation Artificial Intelligence for Diagnosis: From Predicting Diagnostic Labels to "Wayfinding"", JAMA, 326(24):2467–2468. doi:10.1001/jama.2021.22396.
  • Ahmed, S.M., Clasen, M.E., Donnelly, J.F. (1998) "Management of dyslipidemia in adults", American family physician, 57(9):2192-2204.
  • Berberich, A.J., Hegele, R.A. (2021) "A modern approach to dyslipidemia", Endocrine Reviews. doi: 10.1210/endrev/bnab037.
  • Brown, E.E. et al. (2020) "Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association", J Clin Lipidol., Jul-Aug;14(4):398-413. doi: 10.1016/j.jacl.2020.04.011.
  • Cruz-Bautista, I. et al. (2021) "Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia", Lipids Health Dis. 20(1):14. doi: 10.1186/s12944-021-01436-6.
  • Ďurovcová, E., Mareková, M. (2020) "Clinical Biochemistry. 2nd edition", UPJŠ Košice, 275 s. ISBN 978-80-8152-937-5 (pdf)
  • Fredrickson, D.S., Levy, R.I., Lees, R.S. (1967) "Fat transport in lipoproteins-an integrated approach to mechanisms and disorders", New Engl J Med, 276, 34-42.
  • Gaško, R. (2021) "Stanovenie LDL-cholesterolu novými rovnicami Martin a Sampson, porovnanie so starým Friedewaldom na reálnych dátach a na umelom súbore", Vnitr Lek. 67(2):e09-17. doi: 10.36290/vnl.2021.028.
  • Gaško, R. et al. V akej zhode sú výsledky priameho a počítaného stanovenia LDL-cholesterolu v hraničných hodnotách podľa Európskych odporúčaní (2007)? Multicentrická štúdia. Cardiol Letters 2011; 20(6): 468-475.
  • Grundy, S.M. et al. (2019) "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines", J Am Coll Cardiol. 73:e285–350. doi.org/10.1016/j.jacc.2018.11.003
  • Hegele, R.A. et al. (2020) "Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement", Lancet Diabetes Endocrinol., Jan;8(1):50-67. doi: 10.1016/S2213-8587(19)30264-5.
  • Jabor, A., Franeková, J. Kubíček, Z. (2020) "Principy interpretace laboratorních testů: 2., přepracované a doplněné vydání", Praha, Grada Publishing, 456 s. ISBN 978-80-271-1272-2.
  • Kubašta, M. et al. (1972) "Ke snaze klasifikovat hyperlipidémie do typů podle Fredricksona jen na základě koncentrace cholesterolu a triglyceridů v séru", Časopis lékařů českých, 111, č. 24, s. 548-551.
  • Langlois, M.R. et al. (2020) "European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM", Clin Chem Lab Med. 58(4):496-517. doi: 10.1515/cclm-2019-1253.
  • Lippi, G., Plebani, M. (2020) "A modern and pragmatic definition of Laboratory Medicine", Clin Chem Lab Med. 28;58(8):1171. doi: 10.1515/cclm-2020-0114.
  • Mach, F. et al. (2020) "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)", European Heart Journal, 41, Issue 1 111–188. doi.org/10.1093/eurheartj/ehz455
  • Martín-Campos, J.M. (2021) "Genetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and "Missing" Heritability", Biomedicines, 9, 1728. doi.org/10.3390/biomedicines9111728
  • Oravec, S. (2012) "Hyperlipoproteinémie. Úvod do problematiky porúch metabolizmu lipoproteínov", Univerzita Komenského v Bratislave. 71 s. ISBN 978-80-223-3290-3.
  • Quispe, R. et al. (2019) "Characterization of lipoprotein profiles in patients with hypertriglyceridemic Fredrickson-Levy and Lees dyslipidemia phenotypes: the Very Large Database of Lipids Studies 6 and 7", Arch Med Sci, 15 (5): 1195–1202. doi.org/10.5114/aoms.2019.87207
  • Pallazola, V.A. et al. (2020) "Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia)", Arch Med Sci, 16 (5): 993–1003. doi.org/10.5114/aoms.2019.86972.
  • Racek, J. (1999) "Klinická biochemie", 1. vyd. Praha: Galén. 316 s. ISBN 80-7262-023-1.
  • Saadatagah, S. et al. (2021) "Genetic basis of hypercholesterolemia in adults", npj Genomic Medicine, 6:28. doi.org/10.1038/s41525-021-00190-z.
  • Sampson, M. et al. (2021) "A new phenotypic classification system for dyslipidemias based on the standard lipid panel", Lipids Health Dis 20, 170. doi.org/10.1186/s12944-021-01585-8
  • Sampson, M. et al. (2020) A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiology, E1–E9. doi:10.1001/jamacardio.2020.0013
  • Sathiyakumar, V. et al. (2020) "Modern prevalence of the Fredrickson-Levy-Lees dyslipidemias: findings from the Very Large Database of Lipids and National Health and Nutrition Examination Survey", Arch Med Sci. 16(6):1279-1287. doi:10.5114/aoms.2019.86964
  • Sniderman, A. et al. (2007) "Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B", J Clin Lipidol, 1(4):256-63. doi: 10.1016/j.jacl.2007.07.006.
  • Sniderman, A.D. , Tsimikas, S., Fazio, S. (2014) "The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies", J Am Coll Cardiol. 63(19):1935-47. doi: 10.1016/j.jacc.2014.01.060.
  • Sweeney, T. et al. (2021) "The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review", Expert Rev Precis Med Drug Dev, 6(4):247-258. doi: 10.1080/23808993.2021.1930531.
  • Varghese, B. et al. (2021) "Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm", Journal of Clinical Lipidology, 15,1:104-115.e9, doi.org/10.1016/j.jacl.2020.09.011.
  • Visseren, F.L.J. et al. (2021) "2021 ESC Guidelines on cardiovascular disease prevention in clinical practice", European Heart Journal, 42, 3227-3337. doi:10.1093/eurheartj/ehab484
  • Yano, M. et al. (2019) "Comparison of Two Homogeneous LDL-Cholesterol Assays Using Fresh Hypertriglyceridemic Serum and Quantitative Ultracentrifugation Fractions", J Atheroscler Thromb. 26(11):979-988. doi: 10.5551/jat.47191.
  • Zima, T. et al. (2013) "Laboratorní diagnostika. Třetí, doplněné a přepracované vydání", Praha, Galén. 906 s. ISBN 978-80-7492-074-5 (pdf)
  • WHO Memorandum (1970) Classification of Hyperlipidaemias and Hyperlipoproteinaemias. Bull. Wld. Hlth. Org. 43, 891–915.
  • Lipidový konsenzus – 2. Odporúčania pre optimálnu diagnostiku a liečbu dyslipoproteinémií u dospelých (2003) Interná med. 3 (1): 10-18
  • Recommendations of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease: prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992; 2: 113-156.